El papel de rituximab en el tratamiento de la artritis reumatoide

Epstein, 1996, Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience, Arthritis Rheum, 39, 1773, 10.1002/art.1780391102 Matteson, 1995, Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection, Arthritis Rheum, 38, 1187, 10.1002/art.1780380903 Protheroe, 1999, Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma, Rheumatology, 38, 1150, 10.1093/rheumatology/38.11.1150 Edwards, 2001, Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes, Rheumatology, 40, 205, 10.1093/rheumatology/40.2.205 Zhang, 2001, Pathogenesis of rheumatoid arthritis: role of B lymphocytes, Rheum Dis Clin North Am, 27, 335, 10.1016/S0889-857X(05)70205-2 Keystone, 2005, B Cell targeted therapies, Arthritis Research & Therapy, 7, S13, 10.1186/ar1738 Silverman, 2005, Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic, Artritis Rheum, 52, 371, 10.1002/art.20857 Looney, 2004, B cells as therapeutic targets for rheumatic diseases, Curr Opin Rheumatol, 16, 180, 10.1097/00002281-200405000-00003 Kremer, 2005, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial, Arthritis Rheum, 52, 2263, 10.1002/art.21201 Genentech Inc, IDEC, F Hoffmann-La Roche Ltd. Investigator's Brochure for Rituximab (Ro 45-2294) in autoimmune disease, fourth Edition, June 2005. Eisenberg, 2005, The therapeutic potential of anti-CD20 “What do B-cells do?”, Clin Immunol, 117, 207, 10.1016/j.clim.2005.08.006 Edwards, 2004, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N Engl J Med, 350, 2572, 10.1056/NEJMoa032534 Looney, 2004, B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab, Arthritis Rheum, 50, 2580, 10.1002/art.20430 Anolik, 2003, The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus, Arthritis Rheum, 48, 455, 10.1002/art.10764 Leandro, 2005, B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients, Rheumatology, 44, 1542, 10.1093/rheumatology/kei080 Kimby, 2005, Tolerability and safety of rituximab (MabThera), Cancer Treat Rev, 31, 456, 10.1016/j.ctrv.2005.05.007 Tahir, 2005, Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab, Rheumatology (Oxford), 44, 561, 10.1093/rheumatology/keh533 Wolbink G, Vis M, Vrieze H, O Stapel S, Lems WF, Aarden L. Human anti chimeric antibodies (HACA) directed against infliximab do not cross react with adalimumab or rituximab. Abstract 877, presentado en ACR. San Diego Noviembre 11-17 2005. Catuogno, 2005, Serum sickness associated with rituximab in a patient with hepatitis C, Rheumatology (Oxford), 44, 406, 10.1093/rheumatology/keh470 Hamaki, 2001, Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab, Am J Hematol, 68, 292, 10.1002/ajh.10043 Kami, 2003, Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection, Hematol J, 4, 159, 10.1038/sj.thj.6200243 Klepfish, 2003, Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option, Leuk Lymphoma, 44, 349, 10.1080/1042819031000060537 Fleischmann RM, Pavelka K, Baldassare AR, Martin-Mola E, Chatpar PC, Nash PT, et al. Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. Abstract 264. ACR San Diego. Noviembre 2005. Cohen, 2005, Efficacy and safety of rituximab in active R A patients who experienced an inadequate response to one or more anti-TNF-α therapies (REFLEX Study). Abstract 1830, ACR San Diego Sfikakis, 2005, Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial, Arthritis Rheum, 52, 501, 10.1002/art.20858 Stasi, 2001, Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura, Blood, 98, 952, 10.1182/blood.V98.4.952 Levine TD Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52:601-7. Keogh, 2005, Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis, Arthritis Rheum, 52, 262, 10.1002/art.20718 Higashida, 2005, Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment, J Rheumatol, 32, 2109 Cambridge, 2006, Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse, Arthritis Rheum, 54, 723, 10.1002/art.21650 Lehembre, 2006, Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus, Ann Dermatol Venereol, 133, 53, 10.1016/S0151-9638(06)70845-6